# HDP-102

Source: https://onco.cc/drugs/hdp-102/  
OnCo record `hdp-102` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HDP-102 is an experimental antibody-drug conjugate with an amanitin payload from Heidelberg Pharma, in phase 1 trials for non-Hodgkin lymphoma; development is paused.

## Summary

HDP-102 (CD37-ATAC) is an antibody-drug conjugate with an amanitin payload (ATAC) from Heidelberg Pharma. An amanitin conjugate targeting CD37, which is overexpressed on B-cell lymphoma cells. Its furthest stage is phase 1, for non-Hodgkin lymphoma. No clinical trial naming it is registered on ClinicalTrials.gov. First patient dosed end of May 2025; recruitment paused after the first cohort after the September 2025 strategic review, all trial centres closed; partner sought (company page). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: CD37-ATAC
- Tags: pipeline
- Code: HDP-102
- Modality: Antibody-drug conjugate with an amanitin payload (ATAC)
- Mechanism: An amanitin conjugate targeting CD37, which is overexpressed on B-cell lymphoma cells.

## Sources

- Heidelberg Pharma: heidelberg-pharma.com: https://heidelberg-pharma.com/en/research-development/atac-r-projects
- Heidelberg Pharma: heidelberg-pharma.com: https://heidelberg-pharma.com/en/research-development/atac-r-projects

## Connected records

- companies: [Heidelberg Pharma](https://onco.cc/companies/heidelberg-pharma/)

---
JSON: https://onco.cc/api/v1/entities/hdp-102.json